Bounded definition
A hierarchy that keeps biochemical assays, cultured-cell experiments, animal studies, and human in-vivo observations as separate evidence states.
What the cited work establishes
The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Claims: urn:maha:claim:in-vitro-versus-in-vivo-evidence
What remains a separate question
In-vivo evidence is still intervention-, tissue-, dose-, population-, endpoint-, comparator-, and follow-up-specific and does not become universal.
Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
In-vivo genome-editing workflow
inbound connection · method
In-vivo observations are a distinct evidence state from biochemical and cell-culture experiments.
Cell-line versus primary-cell evidence
inbound connection · comparison
Primary-cell evidence remains distinct from organism-level exposure and response.
In-vivo genome-editing workflow
outbound connection · method
The in-vivo workflow supplies one human intervention evidence state.
CHANGE-seq off-target nomination
outbound connection · method
In-vitro nomination supports but does not replace cellular and organism measurements.
Claim ledger
Every proposition keeps its own evidence state.
The cited phase 1 study measures delivery-linked editing effects and early observations in human participants rather than inferring them from an in-vitro assay.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
- Boundary
- In-vivo evidence is still intervention-, tissue-, dose-, population-, endpoint-, comparator-, and follow-up-specific and does not become universal.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · The New England Journal of Medicine
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore, Ed Gane, Julian Taubel, Jingzhu Kao, et al.
- Exact locator
- Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.
- Establishes
- The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
- Boundary
- Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed.